3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
2
Neoplasms
2
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroectodermal Tumors, Primitive
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
lanreotide
3
cabozantinib
3
Nivolumab
3
Everolimus
3
pasireotide
2
lutetium Lu 177 dotatate
2
ganitumab
2
Sunitinib
2
Octreotide
2
Erlotinib Hydrochloride
2
Bevacizumab
2
zimberelimab
1
telotristat ethyl
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
carfilzomib
1
azaspirane
1
aflibercept
1
Temozolomide
1
Somatostatin
1
Random Allocation
1
Ramucirumab
1
Panitumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoid Tumor
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts